First-pass extracted concept

lentiviral vector-mediated β-globin gene addition

Candidate: concept label1 source documents3 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Evidence Snippets

Gene therapy approaches, including lentiviral vector-mediated β-globin gene addition ... have shown promising results in clinical trials and have gained regulatory approval in several regions.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1therapeutic statussupports2025Source 1DOI PubMed

Lentiviral vector-mediated β-globin gene addition has shown promising results in clinical trials and has gained regulatory approval in several regions for β-thalassemia.

Claim 2treatment limitationsupports2025Source 1DOI PubMed

Allogeneic hematopoietic stem cell transplantation for β-thalassemia is limited by donor constraints and procedure-related complications.

Claim 3treatment limitationsupports2025Source 1DOI PubMed

Regular blood transfusions, iron chelation, and supportive care in β-thalassemia remain palliative despite improving patient survival.